# Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

> **NCT05077813** · PHASE2 · UNKNOWN · sponsor: **Kafrelsheikh University** · enrollment: 250 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **COMBINATION_PRODUCT:** 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
- **COMBINATION_PRODUCT:** 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
- **COMBINATION_PRODUCT:** All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)
- **COMBINATION_PRODUCT:** All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
- **COMBINATION_PRODUCT:** 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
- **OTHER:** The standard therapy

## Key facts

- **NCT ID:** NCT05077813
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12
- **Primary completion:** 2022-02
- **Final completion:** 2022-02
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077813, "Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05077813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*